Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 295

1.

Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms.

Koppel C, Schwellenbach H, Zielinski D, Eckstein S, Martin-Ortega M, D'Arrigo C, Schildhaus HU, Rüschoff J, Jasani B.

Mod Pathol. 2018 Jun 26. doi: 10.1038/s41379-018-0071-1. [Epub ahead of print]

PMID:
29946185
2.

Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.

Kitz J, Fokas E, Beissbarth T, Ströbel P, Wittekind C, Hartmann A, Rüschoff J, Papadopoulos T, Rösler E, Ortloff-Kittredge P, Kania U, Schlitt H, Link KH, Bechstein W, Raab HR, Staib L, Germer CT, Liersch T, Sauer R, Rödel C, Ghadimi M, Hohenberger W; German Rectal Cancer Study Group.

JAMA Surg. 2018 Jun 6:e181607. doi: 10.1001/jamasurg.2018.1607. [Epub ahead of print]

PMID:
29874375
3.

Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer.

Fankhauser CD, Schüffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, Hermanns T, Poyet C, Sulser T, Moch H, Wild PJ.

Oncotarget. 2017 Dec 4;9(12):10284-10293. doi: 10.18632/oncotarget.22888. eCollection 2018 Feb 13.

4.

Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.

Scheel AH, Penault-Llorca F, Hanna W, Baretton G, Middel P, Burchhardt J, Hofmann M, Jasani B, Rüschoff J.

Diagn Pathol. 2018 Mar 12;13(1):19. doi: 10.1186/s13000-018-0696-x.

5.

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.

Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T, Heukamp LC, Jasani B, Jöhrens K, Kirchner T, Lasitschka F, Petersen I, Reu S, Schildhaus HU, Schirmacher P, Schwamborn K, Sommer U, Stoss O, Tiemann M, Warth A, Weichert W, Wolf J, Büttner R, Rüschoff J.

Histopathology. 2018 Feb;72(3):449-459. doi: 10.1111/his.13375. Epub 2017 Nov 21.

PMID:
28851100
6.

[Unusual congenital iris finding].

Seiler R, Gunzinger JM, Rüschoff JH, Barthelmes D, Bode PK, Gerth-Kahlert C.

Ophthalmologe. 2018 Mar;115(3):235-238. doi: 10.1007/s00347-017-0530-y. German. No abstract available.

PMID:
28656332
7.

Quality assurance trials for Ki67 assessment in pathology.

Raap M, Ließem S, Rüschoff J, Fisseler-Eckhoff A, Reiner A, Dirnhofer S, von Wasielewski R, Kreipe H.

Virchows Arch. 2017 Oct;471(4):501-508. doi: 10.1007/s00428-017-2142-y. Epub 2017 May 11.

PMID:
28497316
8.

[Hereditary colorectal cancer : An update on genetics and entities in terms of differential diagnosis].

Rau TT, Dawson H, Hartmann A, Rüschoff J.

Pathologe. 2017 May;38(3):156-163. doi: 10.1007/s00292-017-0294-9. Review. German.

PMID:
28474162
9.

Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.

Mortezavi A, Salemi S, Rupp NJ, Rüschoff JH, Hermanns T, Poyet C, Randazzo M, Simon HU, Moch H, Sulser T, Wild P, Eberli D.

Oncotarget. 2017 May 9;8(19):31765-31774. doi: 10.18632/oncotarget.15986.

10.

A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients.

Zhong Q, Guo T, Rechsteiner M, Rüschoff JH, Rupp N, Fankhauser C, Saba K, Mortezavi A, Poyet C, Hermanns T, Zhu Y, Moch H, Aebersold R, Wild PJ.

Sci Data. 2017 Mar 14;4:170014. doi: 10.1038/sdata.2017.14.

11.

HER2 testing in gastric cancer: results of a German expert meeting.

Lordick F, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Möhler M, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Thuss-Patience P, Baretton G.

J Cancer Res Clin Oncol. 2017 May;143(5):835-841. doi: 10.1007/s00432-017-2374-x. Epub 2017 Mar 11. Review.

12.

Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years.

Weyerer V, Schneckenpointner R, Filbeck T, Burger M, Hofstaedter F, Wild PJ, Fine SW, Humphrey PA, Dehner LP, Amin MB, Rüschoff J, Boltze C, Tannapfel A, Zwarthoff E, Lopez-Beltran A, Montironi R, Langner C, Stoehr R, Hartmann A, Giedl J.

J Cancer. 2017 Feb 5;8(3):323-331. doi: 10.7150/jca.17482. eCollection 2017.

13.

[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].

Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Büttner R.

Pathologe. 2016 Nov;37(6):557-567. Review. German.

PMID:
27510417
14.

Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany.

Rüschoff J, Lebeau A, Kreipe H, Sinn P, Gerharz CD, Koch W, Morris S, Ammann J, Untch M; Nicht-interventionelle Untersuchung (NIU) HER2 Study Group.

Mod Pathol. 2017 Feb;30(2):217-226. doi: 10.1038/modpathol.2016.164. Epub 2016 Oct 21.

15.

Neoadjuvant Therapy in Rectal Cancer - Biobanking of Preoperative Tumor Biopsies.

Jo P, Nietert M, Gusky L, Kitz J, Conradi LC, Müller-Dornieden A, Schüler P, Wolff HA, Rüschoff J, Ströbel P, Grade M, Liersch T, Beißbarth T, Ghadimi MB, Sax U, Gaedcke J.

Sci Rep. 2016 Oct 18;6:35589. doi: 10.1038/srep35589.

16.

[HER2 testing in gastric cancer - results of a German expert meeting].

Lordick F, Al-Batran SE, Hofheinz RD, Lorenzen S, Thuss-Patience P, Baretton GB, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Röcken C, Rüschoff J, Tannapfel A.

Z Gastroenterol. 2016 Aug;54(8):791-6. doi: 10.1055/s-0042-110794. Epub 2016 Aug 16. Review. German.

PMID:
27529529
17.

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Buettner R.

Mod Pathol. 2016 Oct;29(10):1165-72. doi: 10.1038/modpathol.2016.117. Epub 2016 Jul 8.

18.

[HER2 testing in gastric cancer : Results of a meeting of German experts].

Baretton G, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Lordick F, Al-Batran S, Hofheinz R, Lorenzen S, Moehler M, Thuss-Patience P.

Pathologe. 2016 Jul;37(4):361-6. doi: 10.1007/s00292-016-0179-3. German.

PMID:
27376648
19.

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.

Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart MJ, Dowsett M, Michiels S, Leyland-Jones B.

JAMA Oncol. 2016 Aug 1;2(8):1040-7. doi: 10.1001/jamaoncol.2016.0339.

PMID:
27100299
20.

Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.

Zhong Q, Rüschoff JH, Guo T, Gabrani M, Schüffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C, Buhmann JM, Perner S, Poyet C, Blattner M, Soldini D, Moch H, Rubin MA, Noske A, Rüschoff J, Haffner MC, Jochum W, Wild PJ.

Sci Rep. 2016 Apr 7;6:24146. doi: 10.1038/srep24146.

Supplemental Content

Loading ...
Support Center